CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Trientine Hydrochloride

Last Updated: May 20, 2021
Result type: Reports
Project Number: SR0680-000
Product Line: Reimbursement Review

Generic Name: Trientine Hydrochloride

Brand Name: MAR-Trientine

Manufacturer: Marcan Pharmaceuticals Inc.

Therapeutic Area: Wilson's Disease

Indications: ​MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.

Manufacturer Requested Reimbursement Criteria1: MAR-Trientine (trientine hydrochloride) to be reimbursed for the treatment of patients with Wilson's Disease who are intolerant to penicillamine.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openMarch 18, 2021
Call for patient/clinician input closedMay 07, 2021
Clarification:

- Patient input submission received from the Canadian Liver Foundation

Submission receivedApril 19, 2021
Submission acceptedMay 03, 2021
Review initiatedMay 04, 2021
Draft CADTH review report(s) provided to sponsor for commentJuly 19, 2021
Deadline for sponsors commentsJuly 28, 2021
CADTH responses on draft review report(s) provided to sponsorSeptember 10, 2021
Expert committee meeting (initial)September 22, 2021
Draft recommendation issued to sponsorOctober 04, 2021
To
October 06, 2021